Dr. Jeffrey Popma, MD, Vice President and Chief Medical Officer for Coronary, Renal Denervation, and Structural Heart at Medtronic discusses Medtronic’s recent CE Mark approval for the Evolut™ FX TAVI System and the increased need for solutions for patients with symptomatic severe aortic stenosis.
Jeffrey Popma, MD, is the Vice President and Chief Medical Officer for Coronary, Renal Denervation, and Structural Heart at Medtronic, a position that he has held since June 2020. Dr. Popma received his BA in Economics from Stanford University and received an MD with the highest distinction from Indiana University School of Medicine. He completed his internship, residency, chief residency in Internal Medicine, and Cardiovascular Fellowship at the University of Texas Southwestern Medical Center in Dallas, TX. He also completed an Interventional Cardiology fellowship at the University of Michigan in Ann Arbor, MI. He has been former interventional faculty at Medstar Washington Hospital Center in Washington, DC and the Brigham and Women’s Hospital in Boston, MA. Dr. Popma was most recently the Director of Interventional Cardiology Clinical Services at the Beth Israel Deaconess Medical Center in Boston, MA, and a Professor of Medicine at Harvard Medical School. Dr. Popma was also the director of the BIDMC Imaging Core Laboratory which completed over 500 studies in coronary, renal denervation, peripheral vascular disease, and structural heart. Dr. Popma has been the national or local investigator for a broad array of new technology, including bare metal stents, drug eluting stents, distal protection devices, total occlusion devices, carotid and peripheral revascularization procedures, and transcatheter valve therapy. Dr. Popma is the Past President of the Society for Cardiac Angiography and Intervention, and a Past Co-Chair of the Interventional Council of the American College of Cardiology. Dr. Popma has served on the editorial boards of numerous publications. He has published over 500 peer-reviewed manuscripts.